Tarsus Pharmaceuticals reaffirms its 2026 net product sales guidance after strong first-quarter XDEMVY performance.
Tarsus Pharmaceuticals has reiterated its 2026 net product sales guidance of $670M to $700M following a robust first quarter for XDEMVY, which generated $145.4M in sales. The company cited strong demand and execution as key drivers behind the results.
The guidance aligns with prior expectations and reflects confidence in sustained growth. Analysts had anticipated a solid quarter, though consensus estimates were slightly below the reported figure. Comparable periods showed steady progress in market penetration.
Shares remained stable as investors digested the update, with no immediate volatility observed in after-hours trading.